Chunlei Guo1,2, Hui Du1,2, Jerome L Belinson3, Chun Wang1,2, Xia Huang1,2, Xinfeng Qu4, Ruifang Wu5,6. 1. Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, No. 1120, Lianhua Road, Shenzhen, Guangdong, 518036, PR China. 2. Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, Shenzhen, Guangdong, PR China. 3. Preventive Oncology International, Inc. Shaker Heights, USA and Cleveland Clinic, Women's Health Institute, Cleveland, OH, USA. 4. Sanming Project of Medicine in Shenzhen Peking University Shenzhen Hospital, Shenzhen, Guangdong, PR China. 5. Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, No. 1120, Lianhua Road, Shenzhen, Guangdong, 518036, PR China. wurf100@126.com. 6. Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, Shenzhen, Guangdong, PR China. wurf100@126.com.
Abstract
OBJECTIVE: To assess the prevalence and distribution of HPV genotypes among Chinese Han women, and to explore the risk of high-grade cervical lesions associated with individual hr-HPV genotypes. METHODS: Genotyping and histopathology data from the Chinese Multi-Center Screening Trial (CHIMUST) and its pilot screening trial, from 6 regions across mainland China, were re-analyzed. The data from physician- and self-collected samples from 10,867 Chinese Han women (ages 30-69) were used to determine the prevalence and distribution of hr-HPV and to explore the risk association between hr-HPV genotypes and precancerous lesions. RESULTS: 9.2% of the study population tested hr-HPV positive in physician-collected sample. The prevalence varied regionally from the lowest in Guangdong (6.3%) to the highest in Inner Mongolia (13.0%). The most prevalent genotypes found were HPV-52 (21.7%), HPV-16 (19.2%), HPV-58 (15.0%), HPV-39 (8.9%), and HPV-51 (8.2%). The overall odds ratios for CIN2+ and CIN3+ for the presence of HPV-16 was 58.6 (95% CI 39.2-87.5) and, 91.6 (95%CI 54.3-154.6), respectively and remained the highest odds ratio for CIN3+ in all 6 regions. CONCLUSION: Geographical variation exists in the prevalence and distribution of hr-HPV in mainland China. HPV-16/52/58 were the most prevalent genotypes, and HPV-16 had the highest risk for high-grade cervical lesions. TRIAL REGISTRATION: CHIMUST, Registration number: ChiCTR-EOC-16008456 . Registered 11 May 2016.
OBJECTIVE: To assess the prevalence and distribution of HPV genotypes among Chinese Han women, and to explore the risk of high-grade cervical lesions associated with individual hr-HPV genotypes. METHODS: Genotyping and histopathology data from the Chinese Multi-Center Screening Trial (CHIMUST) and its pilot screening trial, from 6 regions across mainland China, were re-analyzed. The data from physician- and self-collected samples from 10,867 Chinese Han women (ages 30-69) were used to determine the prevalence and distribution of hr-HPV and to explore the risk association between hr-HPV genotypes and precancerous lesions. RESULTS: 9.2% of the study population tested hr-HPV positive in physician-collected sample. The prevalence varied regionally from the lowest in Guangdong (6.3%) to the highest in Inner Mongolia (13.0%). The most prevalent genotypes found were HPV-52 (21.7%), HPV-16 (19.2%), HPV-58 (15.0%), HPV-39 (8.9%), and HPV-51 (8.2%). The overall odds ratios for CIN2+ and CIN3+ for the presence of HPV-16 was 58.6 (95% CI 39.2-87.5) and, 91.6 (95%CI 54.3-154.6), respectively and remained the highest odds ratio for CIN3+ in all 6 regions. CONCLUSION: Geographical variation exists in the prevalence and distribution of hr-HPV in mainland China. HPV-16/52/58 were the most prevalent genotypes, and HPV-16 had the highest risk for high-grade cervical lesions. TRIAL REGISTRATION: CHIMUST, Registration number: ChiCTR-EOC-16008456 . Registered 11 May 2016.
Entities:
Keywords:
Chinese Han; Distribution; Human papillomavirus; Type-specific prevalence; risk
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Kate T Simms; Julia Steinberg; Michael Caruana; Megan A Smith; Jie-Bin Lew; Isabelle Soerjomataram; Philip E Castle; Freddie Bray; Karen Canfell Journal: Lancet Oncol Date: 2019-02-19 Impact factor: 41.316
Authors: Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray Journal: Lancet Glob Health Date: 2019-12-04 Impact factor: 26.763